First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS (a) of $8.22; First quarter 2025 Dupixent ® global net sales (recorded by Sanofi) ...

The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody ...

Regeneron’s Lynozyfic is a bispecific antibody that works by bridging B-cell maturation antigen on MM cells with ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Arrivent Biopharma, a clinical-stage biopharmaceutical company, has recently appointed Dr. Merdad Parsey, M.D., Ph.D., to its board of directors. Dr. Parsey has extensive executive experience in ...

Regeneron Pharmaceuticals (Nasdaq: REGN) today announced that the European Commission (EC) has granted conditional marketing ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

What lessons can be learnt from treating Trump? Why is his proclamation of Regeneron's unproven and experimental antibody ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...

(NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple ...